-
1
-
-
33645277852
-
Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras
-
Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J. Acquir. Immune Defic. Syndr. 41, 194-200 (2006).
-
(2006)
J. Acquir. Immune Defic. Syndr.
, vol.41
, pp. 194-200
-
-
Crum, N.F.1
Riffenburgh, R.H.2
Wegner, S.3
-
2
-
-
33750999624
-
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
-
DOI 10.1111/j.1468-1293.2006.00424.x
-
Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7, 487-503 (2006). (Pubitemid 44742349)
-
(2006)
HIV Medicine
, vol.7
, Issue.8
, pp. 487-503
-
-
Gazzard, B.1
Bernard, E.J.2
Boffito, M.3
Churchill, D.4
Edwards, S.5
Fisher, M.6
Geretti, A.M.7
Johnson, M.8
Leen, C.9
Peters, B.10
Pozniak, A.11
Ross, J.12
Walsh, J.13
Wilkins, E.14
Youle, M.15
-
3
-
-
48949097660
-
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
-
Most recent International AIDS Society-USA guidelines for antiretroviral therapy
-
Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300, 555-570 (2008). • Most recent International AIDS Society-USA guidelines for antiretroviral therapy.
-
(2008)
JAMA
, vol.300
, pp. 555-570
-
-
Hammer, S.M.1
Eron Jr., J.J.2
Reiss, P.3
-
4
-
-
34249691283
-
Protease inhibitor-based regimens for HIV therapy: Safety and efficacy
-
DOI 10.1097/QAI.0b013e3180600709, PII 0012633420070601100003
-
Walmsley S. Protease inhibitor-based regimens for HIV therapy: safety and efficacy. J. Acquir. Immune Defic. Syndr. 45 (Suppl. 1), S5-S13 (2007). (Pubitemid 46828214)
-
(2007)
Journal of Acquired Immune Deficiency Syndromes
, vol.45
, Issue.SUPPL. 1
-
-
Walmsley, S.1
-
5
-
-
34249711388
-
The role of adherence to antiretroviral therapy in the management of HIV infection
-
DOI 10.1097/QAI.0b013e3180600766, PII 0012633420070601100004
-
Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J. Acquir. Immune Defic. Syndr. 45(Suppl. 1), S14-S18 (2007). (Pubitemid 46828215)
-
(2007)
Journal of Acquired Immune Deficiency Syndromes
, vol.45
, Issue.SUPPL. 1
-
-
Conway, B.1
-
6
-
-
34249047434
-
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)
-
Molina JM, Journot V, Furco A et al. Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). Antivir. Ther. 12, 417-422 (2007). (Pubitemid 46787987)
-
(2007)
Antiviral Therapy
, vol.12
, Issue.3
, pp. 417-422
-
-
Molina, J.-M.1
Journot, V.2
Furco, A.3
Palmer, P.4
De Castro, N.5
Raffi, F.6
Morlat, P.7
May, T.8
Rancinan, C.9
Chene, G.10
-
7
-
-
0037182766
-
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
-
DOI 10.1056/NEJMoa012354
-
Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346, 2039-2046 (2002). (Pubitemid 34680595)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.26
, pp. 2039-2046
-
-
Walmsley, S.1
Bernstein, B.2
King, M.3
Arribas, J.4
Beall, G.5
Ruane, P.6
Johnson, M.7
Johnson, D.8
Lalonde, R.9
Japour, A.10
Brun, S.11
Sun, E.12
-
8
-
-
33746706779
-
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial
-
DOI 10.1016/S0140-6736(06)69155-1, PII S0140673606691551
-
Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368, 476-482 (2006). • The KLEAN study was designed to compare the efficacy and safety of fosamprenavir-ritonavir and lopinavir-ritonavir in treatment-naive patients. (Pubitemid 44160731)
-
(2006)
Lancet
, vol.368
, Issue.9534
, pp. 476-482
-
-
Eron Jr., J.1
Yeni, P.2
Gathe Jr., J.3
Estrada, V.4
DeJesus, E.5
Staszewski, S.6
Lackey, P.7
Katlama, C.8
Young, B.9
Yau, L.10
Sutherland-Phillips, D.11
Wannamaker, P.12
Vavro, C.13
Patel, L.14
Yeo, J.15
Shaefer, M.16
-
9
-
-
49649092719
-
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
-
The ARTEMIS study was designed to compare the efficacy and safety of darunavir-ritonavir with lopinavir-ritonavir in treatment-naive patients
-
Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22, 1389-1397 (2008). • The ARTEMIS study was designed to compare the efficacy and safety of darunavir-ritonavir with lopinavir-ritonavir in treatment-naive patients.
-
(2008)
AIDS
, vol.22
, pp. 1389-1397
-
-
Ortiz, R.1
DeJesus, E.2
Khanlou, H.3
-
10
-
-
49649112490
-
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
-
Original CASTLE study, which details design and primary results. This study was designed to compare the efficacy, safety and tolerability of atazanavir-ritonavir and lopinavir-ritonavir in antiretroviral-naive patients
-
Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372, 646-655 (2008). •• Original CASTLE study, which details design and primary results. This study was designed to compare the efficacy, safety and tolerability of atazanavir-ritonavir and lopinavir-ritonavir in antiretroviral-naive patients.
-
(2008)
Lancet
, vol.372
, pp. 646-655
-
-
Molina, J.M.1
Andrade-Villanueva, J.2
Echevarria, J.3
-
12
-
-
3342924014
-
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
-
DOI 10.1097/00126334-200408150-00003
-
Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36, 1011-1019 (2004) (Pubitemid 38989366)
-
(2004)
Journal of Acquired Immune Deficiency Syndromes
, vol.36
, Issue.5
, pp. 1011-1019
-
-
Squires, K.1
Lazzarin, A.2
Gatell, J.M.3
Powderly, W.G.4
Pokrovskiy, V.5
Delfraissy, J.-F.6
Jemsek, J.7
Rivero, A.8
Rozenbaum, W.9
Schrader, S.10
Sension, M.11
Vibhagool, A.12
Thiry, A.13
Giordano, M.14
-
13
-
-
11144357656
-
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomized open-label trial, the 2NN Study
-
van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 363, 1253-1263 (2004).
-
(2004)
Lancet
, vol.363
, pp. 1253-1263
-
-
Van Leth, F.1
Phanuphak, P.2
Ruxrungtham, K.3
-
14
-
-
3142697068
-
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial
-
DOI 10.1001/jama.292.2.180
-
Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 292, 180-189 (2004). (Pubitemid 38917995)
-
(2004)
Journal of the American Medical Association
, vol.292
, Issue.2
, pp. 180-190
-
-
Saag, M.S.1
Cahn, P.2
Raffi, F.3
Wolff, M.4
Pearce, D.5
Molina, J.-M.6
Powderly, W.7
Shaw, A.L.8
Mondou, E.9
Hinkle, J.10
Borroto-Esoda, K.11
Quinn, J.B.12
Barry, D.W.13
Rousseau, F.14
-
15
-
-
30944468562
-
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
-
Study 934 Group
-
Gallant JE, DeJesus E, Arribas JR et al.; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
-
(2006)
N. Engl. J. Med.
, vol.354
, pp. 251-260
-
-
Gallant, J.E.1
DeJesus, E.2
Arribas, J.R.3
-
16
-
-
38649100026
-
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients
-
DOI 10.1097/QAI.0b013e31815ace6a
-
Malan DR, Krantz E, David N et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 47, 161-167 (2008). (Pubitemid 351172182)
-
(2008)
Journal of Acquired Immune Deficiency Syndromes
, vol.47
, Issue.2
, pp. 161-167
-
-
Malan, D.R.1
Krantz, E.2
David, N.3
Wirtz, V.4
Hammond, J.5
McGrath, D.6
-
17
-
-
62649148454
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naive patients
-
Horberg M, Klein D, Hurley L et al. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naive patients. HIV Clin. Trial 9, 367-374 (2008).
-
(2008)
HIV Clin. Trial
, vol.9
, pp. 367-374
-
-
Horberg, M.1
Klein, D.2
Hurley, L.3
-
18
-
-
65649151755
-
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes
-
Wilkin TJ, McKinnon JE, Dirienzo AG et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J. Infect. Dis. 199, 866-871 (2009).
-
(2009)
J. Infect. Dis.
, vol.199
, pp. 866-871
-
-
Wilkin, T.J.1
McKinnon, J.E.2
Dirienzo, A.G.3
-
19
-
-
33748116898
-
Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study
-
Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43, 27-34 (2006).
-
(2006)
J. Acquir. Immune Defic. Syndr.
, vol.43
, pp. 27-34
-
-
Palella Jr., F.J.1
Baker, R.K.2
Moorman, A.C.3
-
20
-
-
34247537169
-
Class of antiretroviral drugs and the risk of myocardial infarction
-
The DAD Study Group
-
Friis-Møller N, Reiss P, Sabin C et al.; The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723-1735 (2007).
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 1723-1735
-
-
Friis-Møller, N.1
Reiss, P.2
Sabin, C.3
-
21
-
-
33646744190
-
96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
-
DOI 10.1097/01.aids.0000216371.76689.63, PII 0000203020060321000010
-
Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20, 711-718 (2006). (Pubitemid 43884298)
-
(2006)
AIDS
, vol.20
, Issue.5
, pp. 711-718
-
-
Johnson, M.1
Grinsztejn, B.2
Rodriguez, C.3
Coco, J.4
DeJesus, E.5
Lazzarin, A.6
Lichtenstein, K.7
Wirtz, V.8
Rightmire, A.9
Odeshoo, L.10
McLaren, C.11
-
22
-
-
37549038211
-
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial
-
Soriano V, Garcia-Gasco P, VIspo E et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J. Antimicrob. Chemother. 61, 200-205 (2008).
-
(2008)
J. Antimicrob. Chemother.
, vol.61
, pp. 200-205
-
-
Soriano, V.1
Garcia-Gasco, P.2
Vispo, E.3
-
23
-
-
34249078589
-
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week results
-
DOI 10.1086/517497
-
Gatell J, Salmon-Ceron D, Lazzarin A et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin. Infect. Dis. 44, 1484-1492 (2007). (Pubitemid 46801594)
-
(2007)
Clinical Infectious Diseases
, vol.44
, Issue.11
, pp. 1484-1492
-
-
Gatell, J.1
Salmon-Ceron, D.2
Lazzarin, A.3
Van Wijngaerden, E.4
Antunes, F.5
Leen, C.6
Horban, A.7
Wirtz, V.8
Odeshoo, L.9
Van Den Dungen, M.10
Gruber, C.11
Ledesma, E.12
-
24
-
-
30144443508
-
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients
-
DOI 10.1086/498505
-
Jemsek JG, Arathoon E, Arlotti M et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin. Infect. Dis. 42, 273-280 (2006). (Pubitemid 43054203)
-
(2006)
Clinical Infectious Diseases
, vol.42
, Issue.2
, pp. 273-280
-
-
Jemsek, J.G.1
Arathoon, E.2
Arlotti, M.3
Perez, C.4
Sosa, N.5
Pokrovskiy, V.6
Thiry, A.7
Soccodato, M.8
Moor, M.A.9
Giordano, M.10
-
25
-
-
70350667931
-
Reasons for treatment success with initial ART: An analysis of 2635 participants in 64 randomized, controlled trials and 14 prospective cohorts
-
Presented at: Abstract 782
-
Carr A, Amin J. Reasons for treatment success with initial ART: an analysis of 2635 participants in 64 randomized, controlled trials and 14 prospective cohorts. Presented at: 15th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 782).
-
15th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008
-
-
Carr, A.1
Amin, J.2
-
26
-
-
33845495422
-
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
-
DOI 10.1097/QAD.0b013e328011d7c1, PII 0000203020070102000005
-
Rodriguez-Novea S, Martin-Carbonero L, Berreiro P et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21, 41-46 (2007). (Pubitemid 44912535)
-
(2007)
AIDS
, vol.21
, Issue.1
, pp. 41-46
-
-
Rodriguez-Novoa, S.1
Martin-Carbonero, L.2
Barreiro, P.3
Gonzalez-Pardo, G.4
Jimenez-Nacher, I.5
Gonzalez-Lahoz, J.6
Soriano, V.7
-
27
-
-
33847721472
-
Prolonged QT interval and torsades de pointes associated with atazanavir therapy
-
Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin. Infect. Dis. 44, e67-e68 (2007).
-
(2007)
Clin. Infect. Dis.
, vol.44
-
-
Ly, T.1
Ruiz, M.E.2
-
28
-
-
47549110389
-
Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 Case reports
-
DOI 10.1086/589869
-
Gllagher DP, Kieran J, Sheehan G et al. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin. Infect. Dis. 47, e36-e38 (2008). (Pubitemid 352009380)
-
(2008)
Clinical Infectious Diseases
, vol.47
, Issue.3
-
-
Gallagher, D.P.1
Kieran, J.2
Sheehan, G.3
Lambert, J.4
Mahon, N.5
Mallon, P.W.G.6
-
29
-
-
46349105916
-
Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study
-
Vo TT, Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J. Infect. Dis. 197, 1685-1694 (2008).
-
(2008)
J. Infect. Dis.
, vol.197
, pp. 1685-1694
-
-
Vo, T.T.1
Ledergerber, B.2
Keiser, O.3
-
30
-
-
44449142338
-
Stability of antiretroviral regimens in patients with viral suppression
-
DOI 10.1097/QAD.0b013e3282fec415, PII 0000203020080531000005
-
Lodwick RK, Smith CJ, Youle M et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 22, 1039-1046 (2008). (Pubitemid 351769742)
-
(2008)
AIDS
, vol.22
, Issue.9
, pp. 1039-1046
-
-
Lodwick, R.K.1
Smith, C.J.2
Youle, M.3
Lampe, F.C.4
Tyrer, M.5
Bhagani, S.6
Chaloner, C.7
Sabin, C.A.8
Johnson, M.A.9
Phillips, A.N.10
-
31
-
-
25144448034
-
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
-
DOI 10.2165/00003088-200544100-00003
-
Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050 (2005). (Pubitemid 41356390)
-
(2005)
Clinical Pharmacokinetics
, vol.44
, Issue.10
, pp. 1035-1050
-
-
Le Tiec, C.1
Barrail, A.2
Goujard, C.3
Taburet, A.-M.4
-
32
-
-
70350660204
-
Pharmacokinetics (PK) of omeprazole on atazanavir with ritonavir in healthy subjects
-
Presented at: Abstract 658
-
Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetics (PK) of omeprazole on atazanavir with ritonavir in healthy subjects. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005. (Abstract 658).
-
12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005.
-
-
Agarwala, S.1
Gray, K.2
Wang, Y.3
Grasela, D.4
-
34
-
-
67649538485
-
-
Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services. 3 November Most recent Department of Health and Human Services guidelines for antiretroviral treatment
-
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008 www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. • Most recent Department of Health and Human Services guidelines for antiretroviral treatment.
-
(2008)
Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents
-
-
|